LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

Veeva Systems Expands Relationship with Accenture to Help Customers Transition to Vault CRM

May 02, 2023 | Last Trade: US$224.15 4.48 2.04

PLEASANTON, Calif., May 2, 2023 /PRNewswire/ -- 2023 Veeva Commercial Summit, North America  Veeva Systems (NYSE: VEEV) announced an expansion of its business partnership with Accenture to help life sciences companies drive new commercial innovation with Veeva Vault CRM. As companies move to Vault CRM, they have the opportunity to optimize processes to meet the requirements of omnichannel engagement models and today's therapies.

"Accenture is taking its long-standing business partnership with Veeva to new heights by jointly helping our clients reimagine and leverage next-generation commercial capabilities," said Ray Pressburger, managing director and global life sciences commercial practice lead at Accenture.

Veeva and Accenture have supported customers together for over a decade. The expanded relationship is focused on helping Veeva customers in key areas in their move to Vault CRM including migration approach and timing, business process optimization, and leveraging Veeva's existing capabilities and new innovations, such as Vault CRM Service Center and Vault CRM Bot.

"We are excited to expand our long-standing business partnership with Accenture to help our mutual customers optimize customer engagement and gain full advantage of the depth and breadth of Vault CRM," said Tom Schwenger, president and chief operating officer at Veeva. "We are connecting sales, medical, and marketing teams with the right software and data foundation to achieve commercial excellence."

Veeva customers can learn more about Vault CRM at VeevaConnect.com.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Contact:

Alison Borris
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB